{
    "clinical_study": {
        "@rank": "92384", 
        "arm_group": [
            {
                "arm_group_label": "Group TAP block", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this group received a transverse abdominal plan block with local anesthetics and clonidine as postoperative analgesia."
            }, 
            {
                "arm_group_label": "Group : Continuous wound infusion", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this group received continuous wound infusion with local anesthetics and clonidine as postoperative analgesia."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this randomized controlled study is to compare the postoperative analgesic\n      effect of a continuous wound infusion of local anesthetics and a sole transverse abdominal\n      plan (TAP) regional block in the surgery of Abdominoplasty Combined With Flank Liposuction.\n      Local anesthetics products used are ropivacaine combined with clonidine. Similar amount of\n      local anesthetics and clonidine are used."
        }, 
        "brief_title": "Analgesic Effect Between TAP Block and Continuous Wound Infusion in Abdominoplasty Surgery", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Surgery of Abdominoplasty With Flank Liposuction", 
        "detailed_description": {
            "textblock": "In a first group, patients receive, after induction of anaesthesia and before surgery, a TAP\n      block (transverse abdominal plan block) with 3mg/kg Ropivacaine 0.5% (maximum 200 mg) and\n      150 microg Clonidine.\n\n      In a second group, before skin closure, a multiholes catheter was inserted beyond the skin.\n      20 mg Ropivacaine 0.2% added with 150 microg Clonidine was injected as bolus dose through\n      this catheter followed by a continuous infusion of Ropivacaine 0.2% 10ml per hour during the\n      following 9 hours (total dose of 200 mgr)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients scheduled for abdominoplasty combined with flank liposuction\n\n        Exclusion Criteria:\n\n          -  Allergy to local anesthetics or clonidine\n\n          -  Coagulation disorders\n\n          -  History of chronic pain\n\n          -  Alcohol or drugs dependance\n\n          -  Refusal of the patients"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862354", 
            "org_study_id": "2013-00017214-14 2013/9", 
            "secondary_id": "2013-000172-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group TAP block", 
                "description": "Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound", 
                "intervention_name": "Transverse abdominal plan block", 
                "intervention_type": "Procedure", 
                "other_name": "Regional anesthesia : TAP block"
            }, 
            {
                "arm_group_label": "Group : Continuous wound infusion", 
                "description": "In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.", 
                "intervention_name": "Continuous wound infusion", 
                "intervention_type": "Procedure", 
                "other_name": "Regional anesthesia : Continuous wound infusion"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Analgesics", 
                "Anesthetics", 
                "Ropivacaine", 
                "Anesthetics, Local"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Postoperative analgesia", 
            "Abdominoplasty", 
            "Continuous wound infusion", 
            "Transverse abdominal plan block", 
            "Local anesthetics : Ropivacaine", 
            "Regional anesthesia"
        ], 
        "lastchanged_date": "June 3, 2013", 
        "location": {
            "contact": {
                "email": "jplecoq@chu.ulg.ac.be", 
                "last_name": "Jean-Pierre H Lecoq, MD, PhD", 
                "phone": "003243667180"
            }, 
            "contact_backup": {
                "email": "anesrea@ulg.ac.be", 
                "last_name": "Jean-Fran\u00e7ois Brichant, Md, PhD", 
                "phone": "003243667180"
            }, 
            "facility": {
                "address": {
                    "city": "Liege", 
                    "country": "Belgium", 
                    "zip": "4000"
                }, 
                "name": "University of Liege, University Hospital"
            }, 
            "investigator": {
                "last_name": "Jean-Pierre H Lecoq, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparative Analgesic Effect Between Continuous Wound Infusion and Transverse Abdominal Plan Block for Abdominoplasty Surgery", 
        "other_outcome": [
            {
                "measure": "Total of peroperative propofol consumption (mg)", 
                "safety_issue": "No", 
                "time_frame": "at the end of the anesthesia (average time around 180 minutes)"
            }, 
            {
                "measure": "Total of peroperative remifentanil consumption (mg)", 
                "safety_issue": "No", 
                "time_frame": "at the end of the anesthesia (average time around 180 minutes)"
            }, 
            {
                "measure": "Volume of peroperative liquid infiltrated (ml)", 
                "safety_issue": "No", 
                "time_frame": "at the end of the surgery (average time around 150 minutes)"
            }, 
            {
                "measure": "Volume of peroperative liquid suctioned (ml)", 
                "safety_issue": "No", 
                "time_frame": "at the end of the surgery (average time around 150 minutes)"
            }, 
            {
                "measure": "Weight of skin resection (mg)", 
                "safety_issue": "No", 
                "time_frame": "At the end of the surgery (average time around 150 minutes)"
            }, 
            {
                "measure": "Volume of surgical drainage (ml)", 
                "safety_issue": "No", 
                "time_frame": "at day 1 and day 2"
            }
        ], 
        "overall_contact": {
            "email": "jplecoq@chu.ulg.ac.be", 
            "last_name": "Jean-Pierre H Lecoq, MD, PhD", 
            "phone": "003243667180"
        }, 
        "overall_official": {
            "affiliation": "University of Liege, University Hospital", 
            "last_name": "Jean-Pierre H Lecoq, Md, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pain score expressed on a visual analogue scale", 
            "safety_issue": "Yes", 
            "time_frame": "at 0,2,4,6, 8 hours, and day 1 and day 2 postoperatively"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862354"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital of Liege", 
            "investigator_full_name": "J P Lecoq", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Piritramide consumption on Patient Controlled Analgesia (PCA) device", 
                "safety_issue": "Yes", 
                "time_frame": "at 0,2,4,6, 8 hours, and day 1 and day 2 postoperatively"
            }, 
            {
                "description": "Scale of nausea was defined as :\n0 = No nausea - 1 = weak nausea - 2 = Moderate nausea - 3 = Important nausea", 
                "measure": "Scale of nausea", 
                "safety_issue": "Yes", 
                "time_frame": "at 0,2,4,6, 8 hours, and day 1 and day 2 postoperatively"
            }, 
            {
                "description": "Scale of sedation was defined as :\n0 = Awake patient - 1 = Quiet and awake - 2 = Sleepy but arousable - 3 = Sleepy and not arousable", 
                "measure": "Scale of sedation", 
                "safety_issue": "Yes", 
                "time_frame": "at 0,2,4,6, 8 hours, and day 1 and day 2 postoperatively"
            }, 
            {
                "description": "Scale of satisfaction was defined as :\n1 = Very satisfied - 2 = Satisfied with no enthusiasm - 3 = Not satisfied", 
                "measure": "Scale of patient's satisfaction", 
                "safety_issue": "Yes", 
                "time_frame": "at day 2 postoperatively"
            }, 
            {
                "measure": "Number of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "daily during 48 hours postoperatively"
            }
        ], 
        "source": "University Hospital of Liege", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital of Liege", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}